After fluffing its lines in two mid-to-late stage trials in lung and colorectal cancer over the past few years, Daiichi and ArQule had hoped that tivantinib…

Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the London Stock Exchange as it looks to put the…

Takeda and TiGenix have presented 52-week data on their stem cells in Crohn’s disease patients with treatment-refractory complex perianal fistulas.

In an interview with Bloomberg published yesterday, Sage CEO Jeff Jonas was quoted as saying his company was at the top of everyone’s buying list, sending its…

J&J's vet Ross has left for Henry Shein, House E&C Committee staff director Andres takes public affairs job at BIO, and Infinity's Kutok has…

Stanford University scientists converted pancreatic alpha cells to insulin-producing beta cells in mice by blocking the production of a pair of proteins.

uniQure plans to start a three-pronged clinical trial program next year as key assets from its in-house pipeline and Bristol-Myers Squibb collaboration advance…

Prima Biomed has pushed the accelerator on its in-house drug development program, pressing ahead with two trials of its immuno-oncology drug IMP321 in breast…

Juno took a major hit last year when a number of patients died in its experimental CAR-T test, which for months has remained under a cloud and another halt.…